Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in ...

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

Discover how weight loss medications and smart nutrition can silence cravings in Food Noise by Dr. Jack Mosley.

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The pharmaceutical giant has witnessed significant revenue boosts from its ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...